We hypothesized that when the depth of ether anesthesia is increased from 2 to 5%, cerebral vessels di late secondary to circulating catecholamine stimulation of cerebral metabolism. Cerebral blood flow (CBF) by 133Xe clearance and cerebral metabolic rate for oxygen (CMROz) were measured on 2% and then 5% ether in air in two groups of seven monkeys each during mechanical ventilation. Propranolol, 0.5 mg/kg i. v., was infused over 5 min in one group, and the other received saline. All measurements were repeated on 5% and 2% ether. Cere brovascular resistance (CVR) fell by 30%, from 2.28 ± 0.61 (mean ± SD) to 1.51 ± 0.28 mm Hg ml-I 100 g-I min-I (p < 0.01), with the increase in ether from 2 to 5%. CBF and CMROz were unaltered from values of about 45 milOO g-I min-I and 2.3 mi lOO g-I min-I, respectively.
Diethyl ether at 2 relative to 1 times the minimum anesthetic concentration (MAC) (i.e., the anes thetic concentration at which 50% of the subjects move in response to a surgical stimulus) causes ce rebrovascular dilation (Wollman et aI., 1969) . Its effects, at least in humans, are biphasic. At 1 MAC or less, ether decreases both cerebral blood flow (CBF) and cerebral metabolic rate for oxygen (CMR02), whereas at 2 MAC or higher, CBF ex ceeds normal and CMR02 appears to return toward normal. These effects of ether, like those of cyclo propane, have been attributed to increased circu lating catecholamines (Alexander et aI., 1970;  During 5% ether anesthesia, propranolol had no effect on CBF, CMROz, or CVR. On 2% ether, it increased CVR twofold, from 1.5 ± 0.30 to 3.0 ± 1.0 mm Hg ml-I 100 g-I min-I, and decreased CBF by 33%, from 48 ± 8 to 32 ± 10 ml lOO g-I min-I. Plasma epinephrine was two fold higher on 2% compared to 5% ether, both before and after saline or propranolol infusion. In monkeys, cerebro vascular dilation by ether at 5% compared to 2% is not secondary to catecholamine stimulation of CMROz. It may result from a direct effect of either plasma catechol amines or ether on the cerebrovasculature. Key Words: Beta-adrenergic blockade -Catecholamines -Cere bral blood flow-Cerebral metabolism-Ether-Propran-0101. Michenfelder and Theye, 1972) , a hypothesis sup ported by reports of elevated plasma catechol amines in patients during ether and cyclopropane anesthesia (Price et aI., 1959; Hamelberg et aI., 1960) .
Diethyl ether is no longer used for clinical anes thesia, but knowledge of the mechanism of its ef fects on CBF may clarify the factors that mediate the effects of anesthetics on CBF and CMR02. Our aim was to test the hypothesis that the effects of diethyl ether on CBF between 1 and 2 MAC are secondary to stimulation of CMR02 by circulating catecholamines. Thus, we studied the effects of beta-adrenergic blockade with propranolol on CBF and CMR02 during 1-and 2-MAC ether anesthesia in monkeys.
MATERIALS AND METHODS
Fourteen fasted, male cynomolgous monkeys (Macaca fascicularis), weighing 3.0-6.5 kg, were anesthetized with 15% diethyl ether (Fisher Scientific, Inc., Pitts burgh, PA, U.S.A.) in Oz. They were intubated with cuffed endotracheal tubes and mechanically ventilated (Harvard respirator model 607, Harvard Apparatus, Inc., S. Natick, MA, U.S.A.) with 2% ether (end-tidal) in air at 15-20 breaths/min and tidal volumes of about 20 mllkg body weight. End-tidal CO2 (Goddart Capnograph; Dann Co., Inc.) was continuously monitored and controlled at 5% by manipulation of inspired CO2, Dextrose, 5% in 0045% NaCl, was infused intravenously at 5 ml kg-1 h-1 via a 20-gauge Angiocath percutaneously inserted into the cephalic vein. Pancuronium bromide (Pavulon; Or ganon, Inc., West Orange, NJ, U.S.A.), 0.06 mg kg-1 h -I, was intermittently injected intravenously for immo bilization. Rectal temperature was monitored via a rectal thermistor and telethermometer (Yellow Springs, Inc., Yellow Springs, OH, U.S.A.) and controlled at 37 ± 0.5°C by a heated water blanket (Aquamatic module; Gorman Rupp, Inc.). Bipolar electrocardiogram (ECG) leads were attached and ECG recorded on a 12-channel Grass polygraph (Grass model MP-7; Grass Instruments, Quincy, MA, U.S.A.).
Surgical procedures
Surgical procedures were aseptic. Catheters (PE-90; Clay Adams, Inc., Parsippany, NJ, U.S.A.) were in serted into a femoral artery and two femoral veins. Arte rial blood pressure was monitored via a Gould Statham, P23ID strain-gauge transducer (Gould, Inc., Cleveland, OH, U.S.A.) and were recorded on the Grass polygraph. Femoral vein catheters were used for infusion of phenyl ephrine, 10 mg/ml (Neosynephrine), by titrated infusion to maintain mean arterial pressure (MAP) above 60 mm Hg during 2-MAC anesthesia, propranolol (Inderal; Ayerst Labs), and sodium bicarbonate to correct for base deficits, which was always done at least 15 min before measurement of CBF and CMR02 to avoid influencing these measurements.
Catheters (PE-50) were inserted retrograde into the lin gual artery and the tips advanced to the origin of the in ternal carotid artery (verified by palpation) for injection of 133Xe-equilibrated saline and CBF measurements.
Catheters (PE-50) were inserted into the subarachnoid space via craniectomy over the parietal cortex for contin uous monitoring of intracranial pressure (lCP). The tips of the catheters were silastic and multiholed to ensure patency. The catheters were sealed into the dura with cyanoacrylate glue (Kodak 910 glue). Via midsaggital craniectomy, 22-gauge multiholed Angiocaths were in serted into the torcula of the superior saggital sinus for cerebral venous blood sampling.
Experimental protocol
Thirty minutes were allowed for equilibration at end tidal concentrations of 2% ether, as verified by gas chro matography. The end-tidal samples were collected at the peak of expiration in I-ml gas-tight Hamilton syringes. Equilibration was confirmed by two equal end-tidal mea surements obtained 15 min apart. Then, hemispheric CBF was measured by intracarotid injection of 120 fLCi 133Xe. Five minutes later, arterial and cerebral venous blood samples were simultaneously withdrawn for mea suring blood gas tensions and pH, hemoglobin and hemo globin O2 saturation, and plasma epinephrine, norepi nephrine, and ether levels. End-tidal ether concentration was then increased to about 5%, 30 min was allowed for equilibration, and a second set of CBF measurements was obtained. Thereafter, in 7 monkeys, 3 ml normal sa-line was infused intravenously over 5 min (control group), and in the other 7, propranolol (lnderal), 0.5 mg/kg, was infused intravenously over 5 min. Thirty minutes later, a third set of CBF measurements was made. Finally, end-tidal ether was reduced to 2%, and after 30 min, a fourth set of CBF measurements was made.
The end-tidal concentrations of 2% and 5% diethyl ether are approximately 1 and 2 MAC, respectively. MAC for diethyl ether is 1.92% in humans, but is un known in the monkey (Quasha et aI., 1980) . Although we used approximations of MAC, it was not critical, as our primary goal was to compare the effects of high and low levels of ether.
CBF measurements
A 1.25 x 1 inch NaI(T l) flat-field collimated scintilla tion probe with a dorsolateral view of the hemisphere was centered over the parietal cortex and connected to a Nuclear Chicago spectrometer/rate meter whose output was fed into an Accudata analog/digital converter and teletype (Morita et aI., 1979) . Xenon-133, 120 fLCi in 0.2 ml saline, was injected into the ipsilateral internal carotid artery and was immediately followed by 004 ml of hepa rinized (6 IU/ml) saline. Brain 133Xe clearance was moni tored for 15 min after isotope injection. Bicompartmental analysis of the clearance curves by the least-squares method was used to obtain the half-life (tv,) in the fast (gray matter) and slow (white matt� flow compart ments. Mean hemispheric CBF (CBFX) was calculated from the weighted sum of the blood flows in gray (CBFg) and white (CBFw) matter as described by Hoedt-Ras mussen et al. (1966) and James et aI. (1969) , with the fol lowing equations:
where A for gray and white matter was calculated ac cording to the equation:
where S is solubility of Xe in the particular tissue in volved (Veall and Mallett, 1965) ; g or w is gray or white matter; rc is red cell; p is plasma; and Hct is hematocrit.
Plasma ether determination
Plasma ether determinations were performed ac cording to Wolfson et al. (1966) . Ether was extracted from 0.1 ml of whole blood with 1 ml of CC14 and CHC1
Measurements of end-tidal ether concentrations
One milliliter of end-tidal air (sampled at the peak of expiration) was drawn into a gas-lock syringe and in jected into the gas-liquid chromatograph described. Cali bration curves were established with known standards of ether vapor samples derived from their saturated air samples. The saturated vapor pressure of the anesthetic was calculated according to the Antonine equation:
where P is vapor pressure; t is temperature in DC; and A, B, and C are constants. Constants A, B, and C used for ether were 6.785, 994.195, and 220.0, respectively (Dean, 1973) . The volume/volume percent of saturated vapor pressure by atmospheric pressure and multiplying by 100. When higher concentrations of end-tidal ether were as sayed, dilution with room air was required.
Assay of plasma catecholamine
One milliliter of plasma with 2 ng 3,4-dihydroxy phenylalanine (DHBA) internal standard and 50 mg acid washed alumina (AAO) were placed in a 5-ml conical re action vial with 1 ml of 1.5 M Tr is buffer/EDTA (pH 8.6). The vial was shaken for 10 min. Catecholamines and DHBA were adsorbed onto the acid alumina column di rectly from plasma. After aspiration of the plasma, the AAO was washed and aspirated twice with 1 ml of water. The catecholamines and DHB A were eluted with 100 111 of 0.1 M HCI04• After centrifugation, the clear acidic su pernatant was injected directly into a high-performance liquid chromatograph (HPLC) (Waters, Inc., Rochester, MN, U.S.A.) with an electrochemical detector (Bioana lytic Systems, Inc.). Norepinephrine, epinephrine, dopa mine, and DHBA were separated by eluting a reverse phase column with 10% methanol in citrate/EDTA buffer (pH 5.0). Catecholamine concentrations were calculated from known standard calibration curves.
Plasma propranolol determination
Plasma propranolol determinations were performed ac cording to Nation et al. (1978) . For each measurement, 1 ml of plasma, 20 mg of sodium hydrogen sulphite, 0.1 ml of 150 mg/ml of 4-methyl-propranolol hydrochloride (in-ternal standard), 1 ml of carbonate buffer (pH 9.5), and 3 ml of ethyl acetate were placed in a 15-ml screw-cap cul ture tube, vigorously mixed for 1 min, then mechanically shaken for 10 min. After centrifugation at 800 x g for 5 min, the ethyl acetate was transferred to a 5-ml reaction vial containing 0.1 ml of dilute sulfuric acid (pH 2.2). The contents were mixed for 1 min, then centrifuged. A 50-111 aliquot of the acidic phase was injected into the HPLC. Propranolol and methylpropranolol were separated using a Micro-Bondapak alkylphenyl column and a mobile phase of acetonitrile/0.06% phosphoric acid solution (27:73). The effluent was monitored at 205 nm. Propran olol was quantitated by comparing peak-height ratios of samples and known concentration standards.
The data were statistically analyzed by analysis of vari ance for repeated measures and were tested for signifi cance within and between treatment groups with the Stu dent-Newman-Keuls test, with a maximum acceptable significant p value of 0.05. Data are reported as the mean ± SEM unless indicated otherwise.
RESULTS
End-tidal and plasma diethyl ether concentra tions at 1 MAC were similar in both groups, with end-tidal values of about 2.0% and plasma levels of 43 and 57 mg/dl (Table 1) . At 2 MAC, end-tidal ether was about 5.0%, and plasma levels ranged be tween 102 and 170 mg/dl. Thus, the ether concen trations differed by about 2.0-2.5-fold between low and high levels. Plasma propranolol was about 45 ng ml-1 30 min after intravenous infusion. After 60 min, it decreased to about 39 ng ml-1.
Arterial Pco2, Po2, and pH were not significantly different between or within groups. Mean Paco2 ranged between 33 ± 2 and 37 ± 3 mm Hg, Pao2 between 99 ± 5 and 106 ± 7 mm Hg, and pHa be tween 7.38 ± 0.06 and 7.43 ± 0.04. Hematocrit (Hct), however, decreased significantly from 42 ± 5% to 39 ± 3% and 37 ± 4% in the last two mea- At the initial level of I MAC ether, CBFX in the saline and propranolol-treated groups was similar, with mean values of 44 ± 8 and 43 ± 12 ml 100 g-I min -I, respectively (Fig. 1) . Increasing end tidal ether from 2 to 5% had no significant effect on CBFX. However, cerebrovascular resistance (CVR) decreased significantly from 2.28 ± 0.61 to 1.50 ± 0.27 mm Hg ml-I 100 g-I min-I (p < 0.05) in the propranolol group and from 2.10 ± 0.56 to 1.31 ± 0.27 mm Hg ml-I 100 g-I min-I (p > 0.05) in the saline group. The absence of an increase in CBFX with the 50% reduction in CVR was directly related to a 30% reduction in cerebral perfusion pressure (CPP) ( Table 2 ). The reduction in CPP was primarily attributed to a decrease in MAP, although OETHER. PPL (n-7) modest increases in ICP of 3-4 mm Hg were con sistently observed at the higher anesthetic level (Table 2) . CMR02 was clearly unaltered by the in crease in ether from 1 to 2 MAC (Fig. 1) . At 1 MAC, CMROz in the saline and propranolol groups was 2.15 ± 0.85 and 2.27 ± 1.05 ml 100 g-I min-I, respectively, and at 2 MAC, 2.10 ± 0.69 and 1.76 ± 1.07 ml 100 g-I min-I.
At 5% ether, neither propranolol nor saline af fected CBFX compared either between or within groups (Fig. 1) . After propranolol or saline infusion at 2 MAC ether, CVR was similar in the saline and propranolol groups with values of 1.46 ± 0.30 and 1.31 ± 0.27 mm Hg ml-I 100 g-I min-I, respec tively. CPP was similar in the saline and propran olol groups, with values of 60 ± 11 and 66 ± 7 mm Hg, respectively (Table 2 ). CMR02 was unaffected by the infusion of propranolol or saline, with values of 2.09 ± 0.59 and 2.09 ± 0.51 ml 100 g-I min-I, respectively (Fig. 1) .
When end-tidal ether was reduced from 5 to 2% in the propranolol-treated group, CBFX decreased by 33%, from 48 ± 8 to 32 ± 10 ml 100 g-I min-I, whereas in the saline-treated controls, it remained at abou00 mll00 g-I min-I (Fig. 1) . The decrease in CBFX in the propranolol group at 1 MAC was associated with a twofold increase in CVR from 1.46 ± 0.30 to 3.04 ± 1.01 mm Hg ml-I 100 g-I min -I. CVR was independent of ether concentra tion between 1 and 2 MAC in the saline group. De spite these alterations in cerebrovascular tone, CMROz did not change after propranolol infusion at 2 MAC or at 1 MAC ether (Fig. 1) .
Plasma norepinephrine levels were not signifi cantly different between or within groups before or after propranolol or saline infusion and at 1 or 2 MAC ether (Fig. 2) . Plasma epinephrine levels ranged between 1.90 ± 0.59 and 2.40 ± 0.31 ng/ml in the saline group and between 2.89 ± 1.16 and 3.28 ± 1.46 ng/ml in the propranolol group. In con trast to norepinephrine, plasma epinephrine levels varied inversely with the depth of ether anesthesia within both groups, but did not differ between the groups. When the depth of ether anesthesia was in creased from 1 to 2 MAC, plasma epinephrine levels decreased by 50% in both groups. It was un affected by propranolol infusion and returned to baseline when end-tidal ether was reduced to 2%.
DISCUSSION
The results do not support the hypothesis that ce rebrovascular dilation by diethyl ether at 2 relative to 1 MAC is secondary to catecholamine stimula tion of CMR02. Diethyl ether induced cerebrovas cular dilation in the absence of an increase in CMR02. This finding is similar to that observed with cycloproprane, which, like diethyl ether, has a biphasic effect on cerebrovascular tone without af fecting CMR02 (Michenfelder and Theye, 1972) . Although the earlier data obtained in humans sug gested that CMR02 increased toward normal and CBF increased above normal as diethyl ether was J Cereb Blood Flow Metab, Vol. 7, No.2, 1987 increased from 1 MAC to greater than 2 MAC (Wollman et aI., 1969) , the statistical significance of these changes was not stated.
The phenylephrine used to maintain MAP at 60 torr or higher was necessary to avoid severe arte rial hypotension and cerebral ischemic vasodila tion, but was also of potential influence on our re suits. Nevertheless, phenylephrine was used in both groups, and no effect on cerebrovascular tone was seen in the saline controls. If phenylephrine in fluenced cerebrovascular tone, one would expect to see its effect in data from both groups. In humans, intravenous phenylephrine does not affect cerebro vascular tone (Smith et aI., 1970) .
The results do suggest, however, that changes in plasma epinephrine may modulate the effects of ether on cerebrovascular tone. Increasing ether from 1 to 2 MAC decreased both CVR and plasma epinephrine. Furthermore, returning ether from 2 to 1 MAC after propranolol [3-adrenergic blockade elicited a twofold increase in CVR. In contrast, CVR returned to the previous value at 1 MAC in the controls. Plasma epinephrine increased by two fold in both groups. The fact that CVR did not in crease in the saline treated controls when ether was reduced from 1 to 2 MAC despite the increase in plasma epinephrine, clearly indicates that plasma epinephrine had little influence on CVR, at least at the levels measured. The fact that CVR was unal tered with propranolol [3-adrenergic blockade at 2 MAC ether, but was increased significantly at 1 MAC ether, could suggest either a reduced [3-ad renergic tone or increased a-adrenergic tone or both at 1 compared to 2 MAC ether. Under these circumstances, the effects of [3-adrenergic blockade would be observed at 1, but not at 2, MAC ether.
Although our results do not indicate a mqjor role of plasma epinephrine in altering cerebrovascular tone at 1 MAC ether, studies have clearly shown that both exogenous norepinephrine and epineph rine can affect cerebrovascular tone when infused intravenously at a rate of 1 flog kg -1 min -1 in rats (Edvinsson and Owman, 1972) . Norepinephrine re duced CBF in all brain regions by 10-27%, except for the thalamus, mesencephalon, and pons (Ed vinsson et aI., 1979 ). Similar regional responses were observed with epinephrine infusion, except that the magnitude of the reduction in CBF was greater and was in the range of 44-48%. These findings are at variance with those of MacKenzie et al. (1976a MacKenzie et al. ( ,b, 1977 , who showed that if the blood brain barrier was opened with hypertonic urea, nor epinephrine increased CBF and CMR02. The effect could be completely blocked by propranolol, and indeed, the response was a reduction in CBF when propranolol was injected simultaneously with the norepinephrine (MacKenzie et aI., 1977) . The vari able effects of noradrenaline on CBF are likely re lated to the concentration of norepinephrine or epi nephrine achieved in the brain. High brain concen trations achieved by blood-brain barrier opening (MacKenzie et aI., 1976a) or intracerebral release of endogenous norepinephrine (MacKenzie et aI., 1976b) increases CMR02 and secondarily increases CBF, whereas apparently, at lower concentrations, where CMR02 is unaffected, both norepinephrine and epinephrine cause an increase in CVR and a reduction in CBF (Lowe et aI., 1971; Toda, 1983) . The concentrations of exogenous norepinephrine and epinephrine achieved in the different regions of the brain is largely determined by their blood-brain barrier permeability. Norepinephrine and epineph rine are both relatively impermeable, although nor epinephrine is more permeable than epinephrine (Oldendorf, 1971) . Certain regions of the brain, such as the hypothalamus are much more perme able than other regions, suggesting that the CBF and CMR02 effects of exogenous catecholamines probably differ in different brain regions (Weil-Mal herbe et al., 1961) .
In summary, the effects of ether on CVR and CBF probably reflect the complex interaction of several factors, such as alterations in a-adrenergic tone associated with changes in plasma epinephrine levels (Alexander et aI., 1970; Bagwell et aI., 1981) ; alterations in vasoactive metabolites, such as cyclic adenosine monophosphate induced by ether (Mac Murdo et aI., 1981; Sprague et aI., 1974) ; alterations in J3-adrenergic receptor activity mediated directly by ether (Dora and Kovach, 1983) ; and ether-in duced alterations in endogenous catecholamines. The vasodilatory effects of inhalation anesthesia, such as ether and halothane appear to correlate with their effects on brain cyclic adenosine mono phosphate (MacMurdo et aI., 1981) , which for halo thane appear to occur by direct conformational changes in the catalytic subunit of adenylate cy clase, which is unaffected by J3-adrenergic blockade with propranolol (Triner et al., 1971) .
